A. Santoro, M. Magagnoli, M. Spina, G. Pinotti, L. Siracusano et al., gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma, vol.92, pp.35-41, 2007.

J. Radford, P. Mckay, R. Malladi, R. Johnson, A. Bloor et al., Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation, Bone Marrow Transplant, vol.52, issue.3, pp.452-456, 2017.

R. M. Meyer, M. K. Gospodarowicz, J. M. Connors, R. G. Pearcey, W. A. Wells et al., ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma, N Engl J Med. 2 févr, vol.366, issue.5, pp.399-408, 2012.

J. Raemaekers, M. André, M. Federico, T. Girinsky, R. Oumedaly et al., Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial, J Clin Oncol. 20 avr, vol.32, issue.12, pp.1188-94, 2014.

S. Viviani, P. L. Zinzani, A. Rambaldi, E. Brusamolino, A. Levis et al., ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned, N Engl J Med. 21 juill, vol.365, issue.3, pp.203-215, 2011.

D. C. Linch, D. Winfield, A. H. Goldstone, D. Moir, B. Hancock et al., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial, Lancet. 24 avr, vol.341, issue.8852, pp.1051-1055, 1993.

N. Schmitz, B. Pfistner, M. Sextro, M. Sieber, A. M. Carella et al., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial, Lancet. 15 juin, vol.359, issue.9323, pp.2065-71, 2002.

G. L. Shah and C. H. Moskowitz, Transplant strategies in relapsed/refractory Hodgkin lymphoma, Blood. 12 avr, vol.131, issue.15, pp.1689-97, 2018.

M. Rancea, I. Monsef, B. Von-tresckow, A. Engert, and N. Skoetz, High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma, Cochrane Database Syst Rev. 20 juin, issue.6, p.9411, 2013.

G. L. Shah, J. Yahalom, M. J. Matasar, S. L. Verwys, D. A. Goldman et al., Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation, British Journal of Haematology, vol.175, issue.3, pp.440-447, 2016.

E. Jabbour, C. Hosing, G. Ayers, R. Nunez, P. Anderlini et al., Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma, Cancer. 15 juin, vol.109, issue.12, pp.2481-2490, 2007.

R. D. Gentzler, A. M. Evens, A. W. Rademaker, B. B. Weitner, B. B. Mittal et al., F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma, Br J Haematol. juin, vol.165, issue.6, pp.793-800, 2014.

Y. Nieto, U. Popat, P. Anderlini, B. Valdez, B. Andersson et al., Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific highdose chemotherapy regimen on outcome, Biol Blood Marrow Transplant. mars, vol.19, issue.3, pp.410-417, 2013.

A. J. Moskowitz, P. A. Hamlin, M. Perales, J. Gerecitano, S. M. Horwitz et al., Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma, J Clin Oncol. 1 févr, vol.31, issue.4, pp.456-60, 2013.

P. L. Zinzani, S. Viviani, A. A. Vitolo, U. Luminari, S. Zaja et al., Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials, Haematologica. août, vol.98, issue.8, pp.1232-1238, 2013.

H. Ghesquières, A. Stamatoullas, O. Casasnovas, F. Morschhauser, E. Gyan et al., Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients, Leuk Lymphoma, vol.54, issue.11, pp.2399-404, 2013.

A. S. Lacasce, R. G. Bociek, A. Sawas, P. Caimi, E. Agura et al., Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma, Blood. 1 janv, 2018.

J. W. Friedberg, A. Forero-torres, R. E. Bordoni, V. Cline, P. Donnelly et al., Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ?60 years with HL, Blood, vol.28, issue.26, pp.2829-2866, 2017.

B. D. Cheson, Staging and response assessment in lymphomas: the new Lugano classification, Chin Clin Oncol. mars, vol.4, issue.1, p.5, 2015.

M. Meignan, S. Barrington, E. Itti, A. Gallamini, C. Haioun et al., Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma, Leuk Lymphoma. janv, vol.55, issue.1, pp.31-38, 2012.

, CTCAE Files

D. Sur,

N. L. Bartlett, D. Niedzwiecki, J. L. Johnson, J. W. Friedberg, K. B. Johnson et al., Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804, Ann Oncol. juin, vol.18, issue.6, pp.1071-1080, 2007.

A. Josting, H. Müller, P. Borchmann, J. W. Baars, B. Metzner et al., Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma, J Clin Oncol. 1 déc, vol.28, issue.34, pp.5074-80, 2010.

C. H. Moskowitz, M. J. Matasar, A. D. Zelenetz, S. D. Nimer, J. Gerecitano et al., Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma, Blood. 16 févr, vol.119, issue.7, pp.1665-70, 2012.

A. Younes, A. K. Gopal, S. E. Smith, S. M. Ansell, J. D. Rosenblatt et al., Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol. 20 juin, vol.30, issue.18, pp.2183-2192, 2012.

A. J. Moskowitz, P. A. Hamlin, M. Perales, J. Gerecitano, S. M. Horwitz et al., Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma, J Clin Oncol. 1 févr, vol.31, issue.4, pp.456-60, 2013.

, European Cancer Information System

A. Santoro, M. Magagnoli, M. Spina, G. Pinotti, L. Siracusano et al., gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma, vol.92, pp.35-41, 2007.

J. Radford, P. Mckay, R. Malladi, R. Johnson, A. Bloor et al., Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation, Bone Marrow Transplant, vol.52, issue.3, pp.452-456, 2017.

R. M. Meyer, M. K. Gospodarowicz, J. M. Connors, R. G. Pearcey, W. A. Wells et al., ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma, N Engl J Med. 2 févr, vol.366, issue.5, pp.399-408, 2012.

J. Raemaekers, M. André, M. Federico, T. Girinsky, R. Oumedaly et al., Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial, J Clin Oncol. 20 avr, vol.32, issue.12, pp.1188-94, 2014.

E. M. Noordijk, P. Carde, N. Dupouy, A. Hagenbeek, A. Krol et al., Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials, JCO. 1 juill, vol.24, pp.3128-3163, 2006.

S. Viviani, P. L. Zinzani, A. Rambaldi, E. Brusamolino, A. Levis et al., ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned, N Engl J Med. 21 juill, vol.365, issue.3, pp.203-215, 2011.

D. Hasenclever and V. Diehl, A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease, N Engl J Med, vol.339, issue.21, pp.1506-1520, 1998.

S. J. Proctor, J. Wilkinson, and M. Sieniawski, Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future, Crit Rev Oncol Hematol. sept, vol.71, issue.3, pp.222-254, 2009.

, Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study Group, Journal of Clinical Oncology, vol.23, p.22

E. Van-den-neste, O. Casasnovas, M. André, M. Touati, D. Senecal et al., Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant, Haematologica. août, vol.98, issue.8, pp.1185-95, 2013.

P. Brice, R. Bouabdallah, P. Moreau, M. Divine, M. André et al., Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle, Bone Marrow Transplant. juill, vol.20, issue.1, pp.21-27, 1997.

A. Josting, U. Rueffer, J. Franklin, M. Sieber, V. Diehl et al., Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group, Blood. 15 août, vol.96, issue.4, pp.1280-1286, 2000.

F. Morschhauser, P. Brice, C. Fermé, M. Diviné, G. Salles et al., Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group, J Clin Oncol. 20 déc, vol.26, issue.36, pp.5980-5987, 2008.

D. C. Linch, D. Winfield, A. H. Goldstone, D. Moir, B. Hancock et al., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial, Lancet. 24 avr, vol.341, issue.8852, pp.1051-1055, 1993.

N. Schmitz, B. Pfistner, M. Sextro, M. Sieber, A. M. Carella et al., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stemcell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial, Lancet. 15 juin, vol.359, issue.9323, pp.2065-71, 2002.

M. Rancea, I. Monsef, B. Von-tresckow, A. Engert, and N. Skoetz, High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma, Cochrane Database Syst Rev. 20 juin, issue.6, p.9411, 2013.

A. Sureda, C. Canals, R. Arranz, D. Caballero, J. M. Ribera et al., Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study -a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, Haematologica. févr, vol.97, issue.2, pp.310-317, 2012.

A. Sureda, E. Domenech, N. Schmitz, and P. Dreger, Lymphoma Working Party of the European Group for Stem Cell Transplantation. The role of allogeneic stem cell transplantation in Hodgkin's lymphoma, Curr Treat Options Oncol. juin, vol.15, issue.2, pp.238-285, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00849633

C. H. Moskowitz, M. J. Matasar, A. D. Zelenetz, S. D. Nimer, J. Gerecitano et al., Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma, Blood. 16 févr, vol.119, issue.7, pp.1665-70, 2012.

R. Devillier, D. Coso, L. Castagna, B. Rossi, I. et al., Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy, Haematologica. juill, vol.97, issue.7, pp.1073-1082, 2012.

A. Josting, H. Müller, P. Borchmann, J. W. Baars, B. Metzner et al., Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma, J Clin Oncol. 1 déc, vol.28, issue.34, pp.5074-80, 2010.

J. Rodriguez, M. A. Rodriguez, L. Fayad, P. Mclaughlin, F. Swan et al., ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease, Blood. 1 juin, vol.93, issue.11, pp.3632-3638, 1999.

C. H. Moskowitz, A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model, Blood. 1 févr, vol.97, issue.3, pp.616-639, 2001.

D. Villa, T. Seshadri, N. Puig, C. Massey, R. Tsang et al., Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinumcontaining first-line salvage chemotherapy, Haematologica. mai, vol.97, issue.5, pp.751-758, 2012.

D. Sibon, M. Ertault, A. Nawakil, C. De-bazelaire, C. Franchi et al., Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients, Br J Haematol. avr, vol.153, issue.2, pp.191-199, 2011.

F. B. Hagemeister, N. Tannir, P. Mclaughlin, P. Salvador, S. Riggs et al., MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease, J Clin Oncol. avr, vol.5, issue.4, pp.556-61, 1987.

R. Colwill, M. Crump, F. Couture, R. Danish, A. K. Stewart et al., Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation, J Clin Oncol. févr, vol.13, issue.2, pp.396-402, 1995.

M. G. Pfreundschuh, U. Rueffer, B. Lathan, N. Schmitz, O. Brosteanu et al., Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group, J Clin Oncol. mars, vol.12, issue.3, pp.580-586, 1994.

C. Fermé, Y. Bastion, E. Lepage, F. Berger, P. Brice et al., The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease, Ann Oncol. juill, vol.6, issue.6, pp.543-552, 1995.

N. L. Bartlett, D. Niedzwiecki, J. L. Johnson, J. W. Friedberg, K. B. Johnson et al., Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804, Ann Oncol. juin, vol.18, issue.6, pp.1071-1080, 2007.

S. S. Mir, B. Richter, and C. S. Duckett, Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells, Blood. 15 déc, vol.96, issue.13, pp.4307-4319, 2000.

C. A. Smith, H. J. Gruss, T. Davis, D. Anderson, F. T. Baker et al., CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF, Cell. 2 juill, vol.73, issue.7, pp.1349-60, 1993.

J. A. Francisco, C. G. Cerveny, D. L. Meyer, B. J. Mixan, K. Klussman et al., cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity, Blood. 15 août, vol.102, issue.4, pp.1458-65, 2003.

A. Younes, N. L. Bartlett, J. P. Leonard, D. A. Kennedy, C. M. Lynch et al., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas, N Engl J Med, vol.363, pp.1812-1833, 2010.

A. Younes, A. K. Gopal, S. E. Smith, S. M. Ansell, J. D. Rosenblatt et al., Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol. 20 juin, vol.30, issue.18, pp.2183-2192, 2012.

R. Chen, A. K. Gopal, S. E. Smith, S. M. Ansell, J. D. Rosenblatt et al., Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, Blood, vol.22, issue.12, pp.1562-1568, 2016.

M. A. Fanale, A. Forero-torres, J. D. Rosenblatt, R. H. Advani, A. R. Franklin et al., A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies, Clin Cancer Res. 1 janv, vol.18, issue.1, pp.248-55, 2012.

A. Younes, A. K. Gopal, S. E. Smith, S. M. Ansell, J. D. Rosenblatt et al., Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol. 20 juin, vol.30, issue.18, pp.2183-2192, 2012.

P. L. Zinzani, S. Viviani, A. A. Vitolo, U. Luminari, S. Zaja et al., Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials, Haematologica. août, vol.98, issue.8, pp.1232-1238, 2013.

A. Rothe, S. Sasse, H. Goergen, D. A. Eichenauer, A. Lohri et al., Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience, Blood. 16 août, vol.120, issue.7, pp.1470-1472, 2012.

H. Monjanel, L. Deville, C. Ram-wolff, M. Venon, P. Franchi et al., Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients, Br J Haematol. juill, vol.166, issue.2, pp.306-314, 2014.

A. Gibb, C. Jones, A. Bloor, S. Kulkarni, T. Illidge et al., Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center, Haematologica. avr, vol.98, issue.4, pp.611-615, 2013.

A. K. Gopal, R. Chen, S. E. Smith, S. M. Ansell, J. D. Rosenblatt et al., Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma, Blood. 19 févr, vol.125, issue.8, pp.1236-1279, 2015.

R. Chen, J. M. Palmer, S. H. Thomas, N. Tsai, L. Farol et al., Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma, Blood. 28 juin, vol.119, issue.26, pp.6379-81, 2012.

R. Chen, J. Palmer, P. Martin, S. Armenian, N. Tsai et al., Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT, Blood. 3 déc, vol.126, issue.23, pp.519-519, 2015.

R. Garcia-sanz, A. Sureda, S. Alonso-alvarez, A. P. Gonzalez, A. Rodriguez et al., Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO), Blood. 3 déc, vol.126, issue.23, pp.582-582, 2015.

A. Michallet, Y. Guillermin, B. Deau, L. Lebras, S. Harel et al., Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma, Haematologica. juill, vol.100, issue.7, pp.269-271, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02025604

A. F. Herrera, A. J. Moskowitz, N. L. Bartlett, J. M. Vose, R. Ramchandren et al., Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma, Blood. 15 mars, vol.131, issue.11, pp.1183-94, 2018.

C. S. Diefenbach, F. Hong, J. B. Cohen, M. J. Robertson, R. F. Ambinder et al., Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412), Blood. 3 déc, vol.126, issue.23, pp.585-585, 2015.

A. J. Moskowitz, H. Schöder, J. Yahalom, S. J. Mccall, S. Y. Fox et al., PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study, The Lancet Oncology. 1 mars, vol.16, issue.3, pp.284-92, 2015.

C. H. Moskowitz, A. Nademanee, T. Masszi, E. Agura, J. Holowiecki et al., Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet. 9 mai, vol.385, issue.9980, pp.1853-62, 2015.

, +Vedotin&type=Intr&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&s tate=&city=&dist=&locn=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&lupd_s=&lu pd_e=&sort= 55. Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies -ScienceDirect

A. J. Moskowitz, P. A. Hamlin, M. Perales, J. Gerecitano, S. M. Horwitz et al., Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma, J Clin Oncol. 1 févr, vol.31, issue.4, pp.456-60, 2013.

A. Anastasia, C. Carlo-stella, P. Corradini, F. Salvi, C. Rusconi et al., Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi, Br J Haematol. juill, vol.166, issue.1, pp.140-142, 2014.

H. Ghesquières, A. Stamatoullas, O. Casasnovas, F. Morschhauser, E. Gyan et al., Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients, Leuk Lymphoma, vol.54, issue.11, pp.2399-404, 2013.

P. L. Zinzani, U. Vitolo, S. Viviani, P. Corradini, G. Motta et al., Safety and efficacy of singleagent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients, Clin Lymphoma Myeloma Leuk. juill, vol.15, issue.7, pp.404-412, 2015.

G. Corazzelli, F. Angrilli, D. 'arco, A. Ferrara, F. Musto et al., Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma, Br J Haematol. janv, vol.160, issue.2, pp.207-222, 2013.

A. Santoro, R. Mazza, A. Pulsoni, A. Re, M. Bonfichi et al., Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study, J Clin Oncol, vol.34, issue.27, pp.3293-3302, 2016.

M. Kalac, J. K. Lue, E. Lichtenstein, I. Turenne, C. Rojas et al., Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma, Br J Haematol. mars, vol.180, issue.5, pp.757-60, 2018.

A. S. Lacasce, R. G. Bociek, A. Sawas, P. Caimi, E. Agura et al., Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma, Blood. 1 janv, 2018.

O. A. O'connor, J. K. Lue, A. Sawas, J. E. Amengual, C. Deng et al., Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial, Lancet Oncol. févr, vol.19, issue.2, pp.257-66, 2018.

J. W. Friedberg, A. Forero-torres, R. E. Bordoni, V. Cline, P. Donnelly et al., Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ?60 years with HL, Blood, vol.28, issue.26, pp.2829-2866, 2017.

G. L. Shah, J. Yahalom, M. J. Matasar, S. L. Verwys, D. A. Goldman et al., Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation, British Journal of Haematology, vol.175, issue.3, pp.440-447, 2016.

E. Jabbour, C. Hosing, G. Ayers, R. Nunez, P. Anderlini et al., Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma, Cancer. 15 juin, vol.109, issue.12, pp.2481-2490, 2007.

R. D. Gentzler, A. M. Evens, A. W. Rademaker, B. B. Weitner, B. B. Mittal et al., F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stemcell transplantation for relapsed and refractory Hodgkin lymphoma, Br J Haematol. juin, vol.165, issue.6, pp.793-800, 2014.

Y. Nieto, U. Popat, P. Anderlini, B. Valdez, B. Andersson et al., Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome, Biol Blood Marrow Transplant. mars, vol.19, issue.3, pp.410-417, 2013.

R. Garcia-sanz, A. Sureda, A. P. Gonzalez, F. D. Cruz, . La et al., Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO), Blood. 2 déc, vol.128, issue.22, pp.1109-1109, 2016.

A. F. Herrera, A. J. Moskowitz, N. L. Bartlett, J. M. Vose, R. Ramchandren et al., Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma, Blood. 15 mars, vol.131, issue.11, pp.1183-94, 2018.

, Hippocrate Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux. Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur

, J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer leurs consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me sont confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses

, Résumé en anglais

, Brentuximab Vedotin plus Bendamustine: a highly effective salvage treatment in refractory/relapsed patients with Hodgkin Lymphoma. A retrospective, multicentre and collaborative study Introduction: The aim of our study was to assess the efficacy and tolerance of the combination

, Brentuximab Vedotin plus Bendamustine (BV+V) in patients with Refractory or relapsed (R/R) Hodgkin lymphoma (HL) in "clinical routine practice

, Eighty patients (pts) with refractory or relapse (R/R) HL from 15 LYSA centres treated between 2014 and 2017 were retrospectively reviewed. The primary efficacy endpoint was CR after BV+B combination therapy. Secondary endpoints were PR and OR rates, duration of response (DOR), PFS, overall survival (OS), stem cell collection feasibility, Patients and Methods: This a retrospective and multicentre study

, Results: 76 pts were evaluable for efficacy. The CR rate was 68.8%. After a median follow, vol.15, p.7

, Median PFS was not reached, compared to 16 months (14-18) in the group w/o HSCT (p=0.033). Median OS was not reached in both groups. Twenty-three patients (28.8%) experienced grade ? 2 toxicity

, Conclusion: BV+B is an effective salvage therapy in patients with R/R HL. Considering the very good outcome for patients in CR and after ASCT, its use as a "bridge-to-transplantation